LNAI

Lunai Bioworks

3.08 USD
+0.04
1.32%
At close Updated May 29, 4:00 PM EDT
Pre-market
After hours
2.96
-0.12
3.9%
1 day
1.32%
5 days
36.28%
1 month
15.79%
3 months
0.65%
6 months
-70.61%
Year to date
-60.36%
1 year
-87.78%
5 years
-99.07%
10 years
-99.54%
 

About: Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Employees: 29

0
Funds holding %
of 8,058 funds
Analysts bullish %
0
Positive news %
Price charts implemented using Lightweight Charts™